Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain

被引:125
作者
Lorenz, J
Beck, H
Bromm, B
机构
[1] Univ Hamburg, Hosp Eppendorf, Inst Physiol, D-20246 Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Dept Anaesthesiol, D-20246 Hamburg, Germany
关键词
chronic non-malignant pain; morphine; laser evoked potentials; pain measurement; P300; cognitive function;
D O I
10.1016/S0304-3959(97)00123-1
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
This paper investigates subjective, behavioral and neurophysiological changes due to treatment with oral sustained-release morphine in six patients with severe non-malignant pain. Patients rated their mood and clinical pain on visual analog scales (VAS). Experimental pain reactions were quantified by ratings on categorial scales and evoked cerebral potentials (LEP) in response to standardized laser stimuli. A standard auditory oddball task provided reaction time (RT), errors, N1 and P2 of late auditory evoked potentials (AEP), and a P300 component. It was used to measure vigilance and cognitive performance. In parallel with clinical pain reduction, laser pain ratings and LEP amplitudes were significantly reduced. In contrast, auditory P2 and P300 amplitude were found to be even enlarged under morphine. RT and mood also failed to indicate any sedation. It is concluded that LEP indicated the analgesic morphine effects whereas late potentials and P300 from auditory stimuli reflected the perceptual-cognitive status which, instead of being deteriorated by morphine-induced sedation, improved probably due to the removal of pain as a mental stressor. (C) 1997 International Association for the Study of Pain. Published by Elsevier Science B.V.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 30 条
[21]   COMPARATIVE PLACEBO-CONTROLLED PHARMACODYNAMIC STUDIES WITH ZOTEPINE AND CLOZAPINE UTILIZING PHARMACO-EEG AND PSYCHOMETRY [J].
SALETU, B ;
GRUNBERGER, J ;
LINZMAYER, L ;
ANDERER, P .
PHARMACOPSYCHIATRY, 1987, 20 :12-27
[22]  
SCHAREIN E, 1995, PAIN BRAIN NOCICEPTI, P473
[23]   DRIVING ABILITY IN CANCER-PATIENTS RECEIVING LONG-TERM MORPHINE ANALGESIA [J].
VAINIO, A ;
OLLILA, J ;
MATIKAINEN, E ;
ROSENBERG, P ;
KALSO, E .
LANCET, 1995, 346 (8976) :667-670
[24]   EFFECT OF FENTANYL AND NALOXONE ON THE P300 AUDITORY POTENTIAL [J].
VELASCO, M ;
VELASCO, F ;
CASTANEDA, R ;
LEE, M .
NEUROPHARMACOLOGY, 1984, 23 (08) :931-938
[25]  
VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO
[26]  
2-1
[27]   The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals [J].
Villanueva, L ;
Bouhassira, D ;
LeBars, D .
PAIN, 1996, 67 (2-3) :231-240
[28]   The P300 in pain evoked potentials [J].
Zaslansky, R ;
Sprecher, E ;
Tenke, CE ;
Hemli, JA ;
Yarnitsky, D .
PAIN, 1996, 66 (01) :39-49
[29]   ORAL RETARD MORPHINE IN THE LONG-TERM PAIN TREATMENT OF CANCER-PATIENTS [J].
ZENZ, M ;
STRUMPF, M ;
TRYBA, M ;
ROHRS, E ;
STEFFMANN, B .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1989, 114 (02) :43-47
[30]  
ZERSSEN D, 1979, ARZNEIMITTEL-FORSCH, V20, P915